Find Pralatrexate manufacturers, exporters & distributors on PharmaCompass

Pralatrexate

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

5 API Suppliers, 2 USDMF, 1 EU WC, 4 NDC API, 4 Listed Suppliers, $ API Reference Price

5 API Suppliers
2 USDMF
1 EU WC
4 NDC API
4 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

3 Intermediates Suppliers

3 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

11 FDF Dossiers, 4 FDA Orange Book, 1 Canada, 4 Australia, 2 Listed Dossiers

11 FDF Dossiers
4 FDA Orange Book
1 Canada
4 Australia
2 Listed Dossiers

RELATED EXCIPIENT COMPANIES

3 Actylis

relatedExcipients
3 Actylis

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 7 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
7 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

MARKET PLACE

1 APIs, 2 FDF Dossiers

marketPlace
1 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents

patents
4 US Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

304,941

Annual Reports (USD Million)

Finished Drug Prices

3EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 146464-95-1, Folotyn, 10-propargyl-10-deazaaminopterin, Hsdb 7786, Pdx, Pralatrexate(folotyn)

Molecular Formula

C₂₃H₂₃N₇O₅

Molecular Weight

477.5 g/mol

InChI Key

OGSBUKJUDHAQEA-WMCAAGNKSA-N

FDA UNII

A8Q8I19Q20

Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.

Pralatrexate is a Folate Analog Metabolic Inhibitor.

1 2D Structure

Pralatrexate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid

2.1.2 InChI

InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1

2.1.3 InChI Key

OGSBUKJUDHAQEA-WMCAAGNKSA-N

2.1.4 Canonical SMILES

C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O

2.1.5 Isomeric SMILES

C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O

2.2 Other Identifiers

2.2.1 UNII

A8Q8I19Q20

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 10-propargyl-10-deazaaminopterin

2.3.2 Depositor-Supplied Synonyms

1. 146464-95-1

2. Folotyn

3. 10-propargyl-10-deazaaminopterin

4. Hsdb 7786

5. Pdx

6. Pralatrexate(folotyn)

7. Chebi:71223

8. N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-l-glutamic Acid

9. Nsc-754230

10. (2s)-2-((4-((1rs)-1-((2,4-diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic Acid

11. (2s)-2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioic Acid

12. A8q8i19q20

13. 146464-95-1 (racemic)

14. L-glutamic Acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-

15. Ncgc00242596-01

16. (2s)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic Acid

17. (2s)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic Acid

18. N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-l-glutamic Acid

19. L-glutamic Acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-

20. N -(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-l-glutamic Acid

21. Folotyn (tn)

22. Pralatrexate [usan]

23. Pralatrexate [usan:inn]

24. Pralatrexato

25. Pralatrexatum

26. Pralatrexat

27. Unii-a8q8i19q20

28. Pralatrexate [mi]

29. Pralatrexate [inn]

30. Pralatrexate [jan]

31. Pralatrexate [hsdb]

32. Dsstox_cid_28504

33. Dsstox_rid_82776

34. Pralatrexate [vandf]

35. Dsstox_gsid_48578

36. Schembl21633

37. Pralatrexate [mart.]

38. Pralatrexate [who-dd]

39. Gtpl6840

40. Pralatrexate (jan/usan/inn)

41. Chembl1201746

42. Dtxsid3048578

43. Schembl15075302

44. Bcpp000101

45. Pralatrexate [orange Book]

46. Ex-a2142

47. Tox21_112906

48. Bdbm50457437

49. Mfcd00920897

50. Nsc754230

51. S1497

52. Akos015966891

53. Am84423

54. Ccg-269517

55. Cs-0504

56. Db06813

57. Nsc 754230

58. S11194

59. 10-propargyl-10-deazaaminopterin, 95%

60. Ncgc00386226-01

61. Ac-28388

62. Bs-15438

63. Hy-10446

64. Cas-146464-95-1

65. P2645

66. Sw220187-1

67. D05589

68. Ab00443251-02

69. Ab00443251_04

70. 464p951

71. A884505

72. Q637059

73. Sr-01000941578

74. J-008227

75. Sr-01000941578-1

76. N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-l-glutamic Acid;pralatrexate

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₃N₇O₅
Molecular Weight	477.5 g/mol
XLogP3	-0.9
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	10
Exact Mass	477.17606686 g/mol
Monoisotopic Mass	477.17606686 g/mol
Topological Polar Surface Area	207 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	809
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Folotyn
PubMed Health	Pralatrexate (Injection)
Drug Classes	Antineoplastic Agent
Drug Label	FOLOTYN (pralatrexate injection) contains pralatrexate, which is an antineoplastic folate analog. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid. The structural for...
Active Ingredient	Pralatrexate
Dosage Form	Solution
Route	Intravenous
Strength	40mg/2ml (20mg/ml); 20mg/ml (20mg/ml)
Market Status	Prescription
Company	Allos

2 of 2
Drug Name	Folotyn
PubMed Health	Pralatrexate (Injection)
Drug Classes	Antineoplastic Agent
Drug Label	FOLOTYN (pralatrexate injection) contains pralatrexate, which is an antineoplastic folate analog. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid. The structural for...
Active Ingredient	Pralatrexate
Dosage Form	Solution
Route	Intravenous
Strength	40mg/2ml (20mg/ml); 20mg/ml (20mg/ml)
Market Status	Prescription
Company	Allos

4.2 Therapeutic Uses

Aminopterin/ analogs & derivatives; Folic Acid Antagonists

National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)

Pralatrexate is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995

T-cell lymphomas (TCL) are characterized by poor response to chemotherapy and generally poor outcome. While molecular profiling has identified distinct biological subsets and therapeutic targets in B-cell lymphomas, the molecular characterization of TCL has been slower. Surface markers expressed on malignant T-cells, such as CD2, CD3, CD4, CD25, and CD52 were the first TCL-specific therapeutic targets to be discovered. However, the presence of these receptors on normal T-cells means that monoclonal antibody (mAb)- or immunotoxin (IT)-based therapy in TCL inevitably results in variable degrees of immunosuppression. Thus, although some mAbs/IT have significant activity in selected subsets of TCL, more specific agents that target signaling pathways preferentially activated in malignant T-cells are needed. One such novel class of agents is represented by the histone deacetylase (HDAC) inhibitors. These molecules selectively induce apoptosis in a variety of transformed cells, including malignant T-cells, both in vitro and in vivo. Several HDAC inhibitors have been studied in TCL with promising results, and have recently been approved for clinical use. Immunomodulatory drugs, such as interferons and Toll Receptor (TLR) agonists have significant clinical activity in TCL, and are particularly important in the treatment of primary cutaneous subtypes (CTCL). Although most classical cytotoxic drugs have limited efficacy against TCL, agents that inhibit purine and pyrimidine metabolism, known as nucleoside analogues, and novel antifolate drugs, such as pralatrexate, are highly active in TCL. With improved molecular profiling of TCL novel pharmacological agents with activity in TCL are now being discovered at an increasingly rapid pace. Clinical trials are in progress and these agents are being integrated in combination therapies for TCL, both in the relapsed/refractory setting as well as front line.

PMID:20196721 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953129 Erter J et al; Curr Drug Targets (2009) (Epub ahead of print) .

4.3 Drug Warning

FOLOTYN can suppress bone marrow function, manifested by thrombocytopenia, neutropenia, and anemia. Dose modifications are based on ANC and platelet count prior to each dose.

Treatment with FOLOTYN may cause mucositis. If /greater than or equal to/ Grade 2 mucositis is observed, dose should be modified.

Patients should be instructed to take folic acid and receive vitamin B12 to potentially reduce treatment-related hematological toxicity and mucositis. ... Patients should take low-dose oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of FOLOTYN, and dosing should continue during the full course of therapy and for 30 days after the last dose of FOLOTYN. Patients should also receive a vitamin B12 intramuscular injection no more than 10 weeks prior to the first dose of FOLOTYN and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with FOLOTYN.

Although FOLOTYN has not been formally tested in patients with renal impairment, caution is advised when administering FOLOTYN to patients with moderate to severe impairment. Monitor patients for renal function and systemic toxicity due to increased drug exposure.

For more Drug Warnings (Complete) data for Pralatrexate (10 total), please visit the HSDB record page.

4.4 Drug Indication

Treatment of relapsed or refractory peripheral T-cell lymphoma.

FDA Label

treatment of peripheral T-cell lymphoma,

5 Pharmacology and Biochemistry

5.1 Pharmacology

Pralatrexate is a 10-deazaaminopterin analogue of methotrexate. Compared to methotrexate, pralatrexate binds to RTC-1 with 10-times the affinity and is a more potent substrate for FPGS. As a result, pralatrexate is better internalized and retained in cancer cells and is more cytotoxic. Km, pralatrexate = 0.3 mol/L; Km, methotrexate = 4.8 mol/L; Vmax/Km (rate of intracellular transport), pralatrexate = 12.6 Vmax/Km (rate of intracellular transport), methotrexate = 0.9

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

PRALATREXATE

5.2.2 FDA UNII

A8Q8I19Q20

5.2.3 Pharmacological Classes

Folate Analog Metabolic Inhibitor [EPC]

5.3 ATC Code

L01BA05

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01B - Antimetabolites

L01BA - Folic acid analogues

L01BA05 - Pralatrexate

5.4 Absorption, Distribution and Excretion

Absorption

Pralatrexate demonstrates linear pharmacokinetics with a multiphasic decline with both diasteromers over dose range of 30-325 mg/m^2. Bioavailability, nonformulated preparation = 13 - 20%

Route of Elimination

35% of drug is excreted unchanged in the urine (no difference between R- and S- pralatrexate). May be some net renal tubular excretion.

Volume of Distribution

Vss, R-pralatrexate = 37 L Vss, S-pralatrexate = 105 L

Clearance

R- pralatrexate = 191 mL/min S- pralatrexate = 417 mL/min Mean clearance of both enantiomers is 220 mL/min.

The pharmacokinetics of pralatrexate administered as a single agent at a dose of 30 mg/sq m administered as an intravenous push over 3-5 minutes once weekly for 6 weeks in 7-week cycles have been evaluated in 10 patients with PTCL. The total systemic clearance of pralatrexate diastereomers was 417 mL/min (S-diastereomer) and 191 mL/min (R-diastereomer).

Pralatrexate total systemic exposure (AUC) and maximum plasma concentration (Cmax) increased proportionally with dose (dose range 30-325 mg/sq m, including pharmacokinetics data from high dose solid tumor clinical studies). The pharmacokinetics of pralatrexate did not change significantly over multiple treatment cycles, and no accumulation of pralatrexate was observed.

Pralatrexate diastereomers showed a steady-state volume of distribution of 105 L (S-diastereomer) and 37 L (R-diastereomer).

In vitro studies indicate that pralatrexate is approximately 67% bound to plasma proteins.

For more Absorption, Distribution and Excretion (Complete) data for Pralatrexate (7 total), please visit the HSDB record page.

5.5 Metabolism/Metabolites

No involvement of CYP450 enzyme system or glucuronidases.

In vitro studies using human hepatocytes, liver microsomes and S9 fractions, and recombinant human CYP450 isozymes showed that pralatrexate is not significantly metabolized by the phase I hepatic CYP450 isozymes or phase II hepatic glucuronidases.

5.6 Biological Half-Life

12-18 hours

The terminal elimination half-life of pralatrexate was 12-18 hours (coefficient of variance (CV) = 62-120%).

5.7 Mechanism of Action

The selectivity of pralatrexate for cancer cells is based upon the observation that cancer cells generally have an overexpression of reduced folate carrier protein-1 (RTC-1) compared to normal somatic cells. This carrier protein allows the entrance of pralatrexate into the cell. Upon entering the cell, folypolyglutamate synthase FPGS catalyzes the polyglutamination of pralatrexate so that it is retained inside the cell. Once inside, pralatrexate competitively inhibits dihydrofolate reductase (DHFR) and thymidylate synthase. Subsequent depletion of thymidine monophosphate (TMP) occurs so that the cancer cell is unable to synthesize DNA and RNA. As a result, the cancer cell cannot proliferate and is forced to undergo apoptosis. Pralatrexate is more effective against cells that are actively dividing.

Pralatrexate is a folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.

This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methotrexate, and pemetrexed in NCI-H460 non-small cell lung cancer (NSCLC) cells. The tumor growth inhibition (TGI) was assessed using MV522 and NCI-H460 human NSCLC xenografts. Apparent K ( i ) values for DHFR inhibition were 45, 26, and >200 nM for pralatrexate, methotrexate, and pemetrexed, respectively. A significantly greater percentage of radiolabeled pralatrexate entered the cells and was polyglutamylatated relative to methotrexate or pemetrexed. In vivo, pralatrexate showed superior anti-tumor activity in both NSCLC models, with more effective dose-dependent TGI in the more rapidly growing NCI-H460 xenografts. Pralatrexate demonstrated a distinct mechanistic and anti-tumor activity profile relative to methotrexate and pemetrexed. Pralatrexate exhibited enhanced cellular uptake and increased polyglutamylation, which correlated with increased TGI in NSCLC xenograft models.

PMID:19221750 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728224 Izbicka E et al; Cancer Chemother Pharmacol 64 (5): 993-9 (2009).

API SUPPLIERS